Can We Protect Canadian Children from Unsafe Drugs?

Last modified by Jose Gauthier on 2022/04/01 15:28

In 2004, a group of concerned clinician scientists in pediatrics began discussing how to solve problems of drug-induced harm in children. Despite best efforts, adverse events from medication use are a leading cause of morbidity and mortality. But most are never reported, so where to start? We formed the Canadian Pharmacogenomics Network for Drug Safety (CPNDS), a national network among the interested Children’s Hospitals across Canada with the vision to solve the problem of unsafe medication use in children. In 2008, we were recognized and granted the Award for Clinical Research from the CIHR Institute of Human Development, Child and Youth Health for our National Network. Since that time, we have collected clinical data and DNA for more than 100,000 cases of adverse drug reactions and drug matched controls. We have conducted many clinical trials and have published more than 80 studies as a result of this work. We have seen several drug labels add information around the world about pharmacogenetic risk variants that we have uncovered. But what about the original vision? Are we solving the problem? In 2019, Canada enacted the Protecting Children from Unsafe Drugs Act, otherwise known as Vanessa’s Law. How has this worked to improve drug safety? How can these two significant advances work together to best realize the Vision of Solving the Drug Safety Problem for Children. The Webinar will be a brief presentation followed by a panel discussion on key issues of drug safety for children, Vanessa’s Law, pragmatic issues in surveillance for adverse drug reactions and how to move forward to better provide effective and safe drug therapy for Canada’s children. We will bring together experts in drug safety and pharmacovigilance from the Canadian Pharmacogenomics Network for Drug Safety who are focused on creating evidence for safe and effective drug therapy for children and describe the infrastructure and platforms that have logistically facilitated this work.

During this webinar, our presenters will:

1. Describe the burden of adverse drug reactions in children's healthcare

2. Identify pragmatic issues in developing solution strategies for serious adverse drug events pursuant to Vanessa's Law

3. Recognize how a national network approach may address some of these pragmatic issues and better inform safe drug treatment for Canada's children

Dr. Bruce Carleton is a Professor of Pediatrics, Medical Genetics, Population and Public Health, and Pharmaceutical Sciences at the University of British Columbia. He is a Senior Clinician Scientist at the BC Children’s Hospital Research Institute and Director of the BC PHSA Therapeutic Evaluation Unit. He was a member Canadian Agency for Drugs and Technologies in Health Drug Expert Advisory Committee and has served as an advisor to Health Canada, and the US FDA. Dr. Carleton’s research focuses on improving the safety and effectiveness of drug therapy in children. Dr. Carleton has published 16 book chapters, and over 250 peer-reviewed manuscripts and has trained more than 80 fellows and graduate students. His work has resulted in a commercially-available pharmacogenetics panel for children and adults through Dynacare Next Specialized Diagnostics. He is currently the President of the Canadian Society of Pharmacology and Therapeutics.

Dr. Michael Rieder is a Professor in the Department of Paediatrics, Physiology, and Pharmacology and Medicine at Western University, and a CIHR_GSK Chair in Paediatric Clinical Pharmacology. He is a member of the Drug Therapy Committee of the CPS and has served as a consultant to many federal institutes and organizations. His reserach focuses on drug and food safety and optimal therapeutics in children. Dr. Rieder has published 4 books, 33 book chapters, and over 300 peer-reviewed articles, and has trained over 50 fellows and graduate students. His work has resulted in the creation of two new Canadian companies, Adept Diagnostics and Cellsees.

Click here to download the webinar participation certificate.

Tags:
Created by Rachel Van Woezik on 2022/02/01 16:30